Pharming Group (NasdaqGM:PHAR) Q1 2026 Earnings call May 07, 2026 07:30 AM ET Company Participants Anurag Relan - Chief Medical Officer Fabrice Chouraqui - CEO Kenneth Lynard - CFO Leverne Marsh - Chief Commercial Officer Conference Call Participants Benjamin Jackson - Analyst Jeff Jones - Analyst Natalia Webster - Analyst Simon Scholes - Analyst Suzanne Van Voorthuizen - Analyst Whitney Ijem - Analyst None - Analyst Operator Good day, and thank you for standing by. Welcome to the Pharming Group N.V. first ...

公司近期活动 - 公司首席执行官Karen Massey将于2026年5月12日太平洋时间上午10:40，在美银证券2026年医疗健康大会上发表演讲 [1] 投资者关系信息 - 演讲将通过公司官网投资者关系板块进行网络直播，直播结束后约30天内可观看回放 [2] - 公司投资者关系联系人为Alexandra Roy，邮箱为aroy@argenx.com [4] 公司业务与战略 - 公司是一家全球性免疫学公司，致力于改善患有严重自身免疫性疾病患者的生活 [1][3] - 公司通过其免疫学创新计划（IIP）与顶尖学术研究者合作，旨在将免疫学突破转化为一流的创新型抗体药物组合 [3] - 公司已开发并正在商业化首款获批的新生儿Fc受体（FcRn）阻滞剂，并正在评估其在多种严重自身免疫性疾病中的广泛潜力，同时推进其治疗领域内多个更早期阶段的实验性药物 [3]

Leadership transition marks next evolution of growth May 6, 2026 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors. “Karen has earned the full confidence of ...